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Purpose: The purpose of this study was to develop and validate a
symptom-based outcome measure for clinical trials in nonulcer
dyspepsia (NUD).
Methods: Patients referred to me GI outpatient clinic with chronic
upper abdominal pain were approached for this study. Partidpants
with normal endoscopy who met the indusion criteria were enrolled
and dassified into standard subgroups of NUD. The u1cerlike
subgroup received add suppressive therapy and the dysmotilitylike
subgroup received prokinetic agents.
Each subject completed a questionnaire at the initial visit (TI), one
week later before treatment (1'2), and after one month of treatment
(T3). Fach subject selected the symptom most important to them. The
frequency and severity of the selected symptom was recorded as
was a global assessment by the subject of their overall status. Other
data recorded induded a physician global assessment. the subject's
and physician's impression of change in symptoms with treatment.
and the subject's antadd use.
Results: forty-four subjects were enrolled. The primary outcome
measure of the study was the product of the selected symptom's
frequency and severity. Instrument reliability was assessed by
Spearman rank correlation r=O.85 and the intraclass correlation
coeffident - 0.83.
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Good correlation between the measure and patient global assessment
(Irl-596) and between the measure and patient assessment of
treatment response (Irl~584) was noted. The physician global
assessment was moderately telated to the measure (Ir1-.437). Some
relationship was seen between the measure and physician
assessment of treattnent response (IrI=.329). There was no
relationship with change in antadd use (Irl~.143).
Condusion: The main measure was reliable in untreated subjects and
responsive in subjects who responded to therapy. This measure also
appeared to be valid. The method of combining frequency and
severity of the subject-selected symptom into a product was shown
to be a useful means of assessing treattnent effect in NUD patients.
This study documents a reliable, responsive, and valid new outcome
measure for use in clinical trials of NUD.
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Chapter 1 INTRODUCTION·
1 1· Measurement Qf Health:
Medical research today often involves the administration of an
interventiQn to a predefined grQup of individuals fQllowed by the
measurement of response to chat inrexvention. The desired outcome
is an improvement in some aspect of the trial participants' health. To
determine the magnitude of an observed response or lack of
response requires measurement of a health outcome.
A variety of outcomes have been used in clinical trials induding
laboratory tests. objective clinical measures such as morbidity and
mortality rates, and more recently, subjective measures of symptoms
and quality of life. Outcome measurement in the laboratory supplies
objective measurements, for example hemoglobin levels or blood
glucose. which provide little inherent difficulty to the researcher.
Subjective judgment is generally not required. Clinical aial research
in the past concentrated on assessments which usually did not
require subjective opinions. These outcomes, for example.. might be
prolongation of life or prevention of a life threatening condition such
as cancer or heart disease. Measurement of mortality and
occurrences of dearly defined conditions such as a myocardial
infarction was relatively straightforward. In more recent times. the
situation has become more complex. The effect of new drugs on
quantity of life is likely to be marginal. Now researchers are more
aware of the importance of the impact of an intervention on quality
of life (1). QIlality Qf life is now used as a ptimaryQutcome measure
to determine patient response to various interventions. Such
outcomes have been utilized in a variety of trials in areas as diverse
as cancer (2), joint disease (3), heart disease (4), and chronic lung
disease (5). Qpality of life however cannot be measured in the
laboratory. New sdentific methods are necessary to measure quality
of life in a consistent. meaningful manner.
To begin to measure quality of life first requires an understanding of
what exactly constitutes health. Most \'Videly accepted in the past \Va5
the traditional medical model of health. This model defined health as
the absence of disease and infirmity. The medical model bas been
criticized for ignoring social health and the importance of interactions
with others (6). A recent holistic model includes physical as well as
meotal and sodal aspects of health as defined by the World Health
Organization. The World Health Organization definition states health
is "A state of complete physical. mental. and social well-being and
not merely the absence of disease and infirmity" (7).
To measure quality of life obliges the investigator to consider all
aspects of health. The d.rcumstances of a person's health can be
assessed objectively by the physician or subjectively by the person.
One's subjective perception of health can be influenced by
experieoce, belief, or expectations (8). Expectations regarding health
and one's ability to cope with limitation can affect perception of
health, therefore two people with the same objective health status
may have very different qualities of life. Relying solely on objective
dara may omit relevant details such as a patient's ability to tolerate
discomfort (8). Physical and psychological componeots of disease are
not mutually exclusive and their impact on a person's impression of
health should not be ignored.
Today, in medical research, situations may confront the investigator
where no objective measures of illness exist and where quality of life
measures are either not available or not applicable. rn this instance
the investigator must measure the symptomatic response to an
intervention. Functional bowel diseases provide a good example.
These conditions consist of variable combinations of gastrointestinal
complaints for which no cause is known. Since there are no objective
measures of patient illness, no objective measures of response to an
intervention are available. The researcher therefore must use
subjective symptom-based outcome measures to determine the
magnirude of a response to therapy.
1.2: Types of Quality of life MeasureS'
Quality of life measurements fall into two categories, generic and
disease-specific instruments. Generic instruments are designed to
sample the complete spectrum of function or disability relevant to
quality of life. Disease-specific instruments concentrate on certain
conditions or factors related. to the condition or disease of interest.
Health related quality of life instruments are made up of a number
of items or questions. These items are grouped in a number of
domains or dimensions which refer to the area of behaviour or
experience being measured. Domains might indude physical function
or emotional function, for example (9).
There are two main types of generic instruments. health profiles and
utility measures. Health profiles use a single instrument to measure
different dimensions or aspects of quality of life. A common scoring
system is shared which can be aggregated into a small nwnber of
scores or even a final single score or index. An example is the
Sickness Impact Profile (SIP) (10). The SIP assesses sickness-related
dysfunction in 12 different categories producing a score for each
category. Various categories can be combined into a physical
dimensions score, a psychosocial dimension score, and an overall
score with independent categories of w:>rk, eating. sleep and rest,
home management, and recreation and pastimes (11). Overall SIP
scores for well populations are low and scores for patients Mth
chronic debilitating illnesses such as rheumatoid arthritis are high.
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The SIP has been used in srodies of cardiac rehabilitation (12), total
hip arthroplasty (13), and treatment of back pain (14).
Health profiles allow determination of the effects of an intervention
on different aspects of quality of life such as emotional dysfunction
without the need for multiple instruments. Health profiles can also
be used in a wide variety of conditions (15). There are also
disadvantages assodated with the use of health profiles. The
generality of their design limits their applicability to more specific
aspecrs of quality of life. in addition, health profiles may not focus on
specific aspects of interest, therefore resulting in an unresponsive
instrument that fails to detect small but clinically important changes
in quality of life (16, 17).
Utility measures, which are derived from economic theory, indicate
the preferences of patients for treatment and outcome. Quality of life
is measured holistically as a single number along a continuum of
death 0.0 to full health 1.0. There are "'"' approaches to utility
measures. One method involves asking a number of questions and
depending on their responses, patients are assigned to one of a
nwnber of categories. These categories have previously been
assigned utility values by a different sample of raters. An example of
a utility measure using this approach is the widely used quality of
well-being scale (18). The second approach entails asking patients to
assign a single utility which describes their quality of life. This can
be accomplished a number of ways. One methcxi is the standard
gamble in which subjects are asked to choose becween their own
health state and a gamble that they may die immediately or achieve
full health for the rest of their lives. The quality of life is determined
by the choices made as the probabilities of immediate death or full
health are varied. A simpler method involves the time trade-off
method. Subjects are asked how many years in their present health
state would they be willing to trade-off for a shoner life span in full
health (19).
The major advantage of utility measures is their ease of use in cost-
utility analysis, in which the cost of an intervention is related to the
number of quality-adjusted life-years (QALYs) gained (15). Utility
measures are limited in a number of ways. The measurements can
vary depending on how they were obtained, therefore the validity of
a single measurement can be questioned (20). Secondly, one cannot
determine which aspects of quality of life are responsible for changes
in utility. Finally. utility measures may not respond to small but
clinically important changes in patient status (21).
Disease-specific instruments focus on limited aspects of health status.
The rationale for focusing on specific items lies in the potential of
increased responsiveness to change. The instrument may concentrate
on certain aspects of interest to the investigator such as a specific
disease (e.g. chronic lung disease), a specific population of patients
(e.g. the frail elderly), or a specific problem (e.g. pain) caused by
various diseases. Disease-specific instruments have been developed
for many conditions induding cardiovascular disease (22), arthritis
(23), and cancer (2,24).
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Disease-spedfic insauments have a number of advantages and have
been proven useful in clinical trials (22. 25). Disease-specific
instruments concentrate on certain features found in the patient
group of interest. For e>cample, in chronic lung disease a quality of
life measure induded details of dyspnea., day-to-day activities,
fatigue, and emotional problems (25). The items used were generated
from input of patients with chronic obstructive lung disease who
selected questions important to them. Recipients of the measure
were questioned about activities which make them short of breath
and how short of breath they have been doing selected activities in
the two weeks prior to being assessed.
As well, specific measures can concentrate on symptoms of interest
to physicians such as bowel dysfunction in patients with
inflammatory bowel disease. When the Inflammatory Bowel Disease
Questionnaire was being developed. an expert panel of care givers
was asked to list symptoms of mo thought to be important to them.
Consequently, because of the concentration on specific, important
items. disease-sped.fic measures demonstrate increased.
responsiveness to changes in quality of life (26. 27). The major
disadvantage of disease-specific measures is that this type of quality
of life instrument is not comprehensive. Disease-specific instruments
cannot compare across different diseases and therefore have limited
generalisability.
Q]Jality of life instruments can also be caregorized as discriminative,
predictive, and evaluative indices depending upon their role.
Discriminative indices distinguish between individuals or groups
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with respect to an underlying dimension when no gold standard
exists. An example would be an index applied to patients following
myocardial infarction to divide them into those with good and those
with poor quality of life, with a view to possible intervention in the
latter group. Predictive indices classify individuals into a set of pr~
defined measurement categories either at initial assessment or at
some lime in the future. A gold standard is usually compared to
determine whether these individuals have been classified correctly.
An example might be the use of intelligence testing by l.Q.
measurements in order to predict future performance in university.
The future performance of the partidpants in university would be
the reference measure or gold standard. Evaluative indices measure
the magoitude of aoy longitudinal change in individuals or groups.
Evaluative indexes are the main type of quality of life measurement
used in clinical trials (21). An example would be the Inflammatory
Bowel Disease Q!lestionnaire (mDQ) which has been developed for
use in patients with lnfIammatory Bowel Disease (28). The moo.
examined four aspects of patient lives: symptoms related directly to
the primary bowel disturbance such as frequency of defecation or
atxiominal cramping, systemic symptoms such as ma.laise or fatigue,
emotional function, and soda1 function. Administration of the
instrument generates scores which have been shown to change as the
patient's status changed. A worsening in the IBOQscores correlates
with worsening of the patients disease state.
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1 3' Symptom-Based Outcome Measures:
A variety of approaches have been used to measure symptoms in
clinical research. An overview of this type of measurement and its
development is well described by Streiner and Norman and the
following section is condensed from this v.<>rk.( 1)
When developing scales to measure symptoms it is necessary to
consider the possible responses. ReSJX>nses can be basically divided
into categorical responses such as religion and marital status and
continuous variables like blood pressure and hemoglobin levels. The
second feature to be considered is the "level of measurement". If the
response consists of Damed categories such as particular symptoms
or job classifications, the variable is referred to as a nominal
variable. If the variable consists of ordered categories, such as colon
cancer staging, it is an ordinal variable. This is in contrast to
variables where the interval between the response and the constant
is known. In this situation the Variable is referred. to as an interval
variable. An example is measurement of body temperature using the
Celsius scale. The final type of variable is the ratio variable where
there is a meaningful zero point SO that a ratio of two responses has
meaning (e.g. temperature Kelvin). The important distinction lies
between nominal and ordinal data which are considered as
frequendes in individual categories and use non-parametric statistics
for analysis, and interval and ratio variables which are continuous
variables and require parametric statistics for analysis.
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One simple fonn of a categorical scale is a yes-no a.IlS¥t'er. The
response would result in a nominal scale of measurement. The most
common error made when using this type of measure is use of
categorical questions when the response is not categorical. For
example the question "Do you have trouble climbing stairs?" ignores
the fact that there are varying degrees of trouble climbing stairs. The
researcher probably wishes to find out how much trouble one has
climbing stairs. [gnoring the continuous nature of many responses
leads to two problems. Different people will have different ideas of
what constitutes a positive response, therefore error is introduced.
secondly, error is introduced by the limited number of available
responses, leading to loss of information and less reliability.
Three catagories of methods are available to researchers using
continuous variables of interest. These include direct estimation
techniques in which the subject is required to indicate their response
by a mark on a line or a check in the box, comparative methods in
which subjects choose among a series of alternatives which have
been previously calibrated. by a separate criterion group, and
econometric methods in which numerical values are assigned to
various health states to allow determination of costlbenefit ratios.
The direct estimation techniques have been used widely by clinical
researchers for symptom-based outcome measures. These methods
include visual analog scales (VAS) and adjectival scales.
Visual analog scales consist of a line of fixed length, usually 10 an.,
with anchors such as "no pain" and "pain as bad as it could be" at the
extreme ends with no 'M:>rds describing the intermediate portions.
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(See figure 1 below.) The respondents are required to place a mark
on the line corresponding to their perceived state. VISual analog
scales have been used in medidne to assess a variety of constructs
such as pain (29), mood (30), and functional capadty (31).
Figure 1.1: Example of visual analog scale.
How bad has your pain been today?
DO pain pain as bad as
it could be
Visual analog scales probably provide no more valid information
than well designed adjectival scales, however they are very popular
because their design and use is relatively simple. Unfortunately, not
all patients find VAS simple. Huskisson reported 7% could not
complete a VAS rating pain severity although no details were given
as to the reasons why (29). A change of categories on a discrete scale
may be easier to grasp intuitively then a change of 10 to 20 nun. on
a 100 nun. line of the visual analog scale.
Adjectival scales consist of adjectival descriptions and discrete or
continuous responses. These specific scales are very popular and are
in widespread use. Adjectival scales are measures where the rater
expresses an opinion by rating his agreement with a series of
statements (See figure 2). Adjectival scales are widely referred to as
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liken scales. The use of the term "liken scale" in lieu of categorical
or adjectival scale is incorrect. A liken scale is one type of adjectival
scale which uses responses framed as a continuum. of agree to
disagree (32). The example of an adjectival scale seen below in
Figure 2 is a liken scale. In this example, the given responses range
from agree to disagree. This is contrast, for example. to a scale with
the response options of: none, mild, moderate, severe, and vel')'
severe.
Figure 1.2: Example of an adjectival scale.
In your opinion, is Jean Chretien worse than previous prime
ministers of Canada?
strongly
agree
agree neutral disagree strongly
disagree
Adjectival scales are popular tool.s for measuring symptom change in
clinical trials. They are easy to design, are easily understood by
subjects, and require less pre-testing than comparative methods.
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1.4: Characteristics of a Subjective Health Measure:
Whenever subjective endpoints such as symptoms or quality of life
are used to determine outcome, three requirements must be met by
the measure (33, 34). The measure must be reproducible. It should
be responsive or able to detect change. Fmally, the measure should
be valid Le. measure what it is supposed to measure.
Reprodudbility or reliability can be defined as the extent to which a
measuring procedure yields the same results on independent
repeated trials under the same conditions (11). While repeated
measurements of the same phenomena are never exactly the same,
they should be consistent. The difference that arises or variance can
be explained by error. Any measurement will contain a certain
amount of chance or random error. The amount of random error is
inversely related to the reliability of the instrument. For example, if
a rifle fires shots widely scattered around the target, it is considered
to be unreliable. If, however, the shots are concentrated around the
target, the rifle is considered to be reliable. Random error is also
unsystematic, therefore the rifle shots will not deviate in a
systematic or consistent fashion. Another type of error is non
random or systematic error. For example, the rifle whose shots are
aimed at a bull's eye, but are dusterec1 together three inches away
from the target, is affected by some type of non random error or
bias.
Classical measurement theory presupposes that an observed score
consists of the true score plus an error temL This leads [Q the
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reliability coeffi.dent as the ratio of the true variance to the true
variance plus the error variance. It is too simple however to assume
that all variance in scores can be neatly divided. into true and error
variance. The generalizability theory ofCronbach (35) states that in
any measurement there are multiple sources of variance. A goal of
measurement is to identify and measure these various components
in order to implement strategies to reduce their effects on the
measurement (1). This ultimately leads to a more reliable measure.
Responsiveness. or Sensitivity to change, refers to the instrument's
ability to detect clinically important change over time or after
treatment. Responsiveness is determined by two properties. To be
responsive an instrument must be reliable. Secondly, an instrument
must register changes in score when a subject's condition changes for
better or worse (36). The responsiveness of an instrument may be
limited by ceiling or floor effects. For example. a ceiling effect might
occur if patients with the best score still have substantial
impairment. Further improvement would not be reflected. by an
increased score. likewise, floor effects can occur when patiencs who
already have the worst possible scores deteriorate further (9). In
other words, the instrument must also be able to detect the full
range of possible responses to be truly responsive.
Validity is a necessary property of any test or instrument. The
insrrwnent must measure what it is supposed to measure (37). There
are several types of validity which are relevant for subjective
measures.
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Criterion validity refers to the correlation of a new measure with
some other reference generally accepted as the best available
measure of the disorder under study. Criterion validity can be
divided into twO types, concurrent and predictive. Concurrent
validity involves correlation of the new measure and the criterion at
the same time. For example, a new scale of depression could be
administered simultaneously with the Beck Depression Inventory (an
accepted measure of depression). Predictive validity infers that the
criterion will not be available until sometime in the future, as one
would see with a new diagnostic test where it is necessary to wait for
a post-mortem examination to confirm predictions (1). Criterion
validity has been used mainly to analyze the validity of certain types
of tests and selection procedures. Unfortunately, in many instances in
clinical medicine, a relevant criterion does not exist.
A second type of Validity is content validity. Content validity
examines the extent to which the domain of interest is sampled by
the instrument. induding choice of and importance of items on a
questionnaire (21). For example, a test of arithmetic operations
would not be content valid if only addition problems 'Were assessed,
exduding problems of subtraction, division.. and multiplication. A
measure that indudes a representative sample of content domains
lends itself to more accurate inferences. [f important aspects are
missing, the researcher is more likely to make some inferences that
are wrong (1).
Face validity refers to whether items on a questionnaire appear to
make sense and can be easily understood (38). Is the questionnaire
lS
easy to use? Are any of the questions or items in the measure
confusing or undear? These questions can be answered with a small
pilot study before further testing occurs.
When criterion validity is not applicable. the most rigorous means of
establishing validity is construct validity. A construct is a
theoretically derived notion of the dimension to be measured.
Determining construct validity involves examining the relationship
that might exist between the instrument and the patient group to be
studied. The investigator hypothesizes how the instrument should
relate to other measures. These measures or constructs are applied to
the population of interest. Validity is strengthened or weakened
when the hypotheses are confirmed or refuted To demonstrate
construct Validity of an new instrument for patients with heart
failure, an investigator may vvant to show that patients with poorer
exercise testing score lower in aspects of the new measure that relate
to physical function, and that global ratings of quality of life by the
patient, relatives, and health workers bear a dose relation to the
results of the new index (21). The validity of an evaluative
instrument is suggested when changes in the instrument correlate
with changes in the other related measures (9).
Validity is not an all or nothing situation. Validation continues with
further use of the instrument as in future clinical trials. The more an
instrument is used and the more situations in which it is used, the
greater the confidence in its validity. Guyatt has stated "perhaps we
should never condude that a questionnaire has "been validated" but
16
rather we should suggest that strong evidence for validity has been
obtained in a number of different settings and studies" (9).
17
Chapter 2: DEVE! DPMENT DF A S!!BIECTIVE HEALTH MEASURE'
2 1: Inqaduqion°
The actual technique of developing a subjective instrument for use in
clinical trials has been desaihed in detail by Guyan (26). The
strategy of developing such indexes involves six stages (37): item
selection, reduction of number of items, questionnaire format.
pretesting, reprodudbility and responsiveness, and validity. These
will be discussed individually in the following sections.
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2 2: Item. Selection:
Items used on a questionnaire must be represencative of me
problems faced by patients with the condition to be studied.
lnterviews can be performed on a random sample of patients in
order to determine items of interest. Patients are asked to rate the
frequency and importance of each item to themselves using a
adjectival scale (very important to not important at all). A second
approach is to compile a set of items before interviewing the patient
sample. Appropriate items may be obtained by reviewing the
current literature, polling content experts, and!or examining pre-
existing questionnaires for patients with similar conditions. An
example of a measure developed using this process is the
Inflammatory Bowel Disease Q].lestionnaire. A list of items for use in
this questionnaire was generated by administering questionnaires to
clinicians who cared for patients with inflammatory bowel disease on
a daily basis and to patients with inflammatory bowel disease,
reviewing the literature of inflammatory bowel disease, and utilizing
items from other disease-specific instruments (39).
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2.3: Reduction of the Number of Items selected;
Generally the item selection process yields more items than can be
used.. The number of items may be reduced, however certain criteria
are important to maintain an appropriate sample. These include the
number of subjects who selected the item (item frequency), the
imponance attached to each item. and the relevance of each item. An
approach which has been used is to combine frequency and
importance criteria by multiplying the frequency of each item by its
mean importance. Items with the greatest frequency-importance
product are retained for the final questionnaire.
[n order to assess an intervention with specific goals, items relevant
to those goals must remain in the questionnaire. Each dimension or
symptom to be measured must be adequately represented to reduce
the variability of response and to reduce the impact of idiosyncratic
responses.
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2.4: Fonnat of the Instrument:
To ensure responsiveness, each scale must be able to detect small
changes if these occur. A number of characteristics are recommended
for subjective scales to improve responsiveness. Scales must be
composed of individual elements which are dearly defined. In other
words, the ranks must be non-overlapping and discrete. [f not, the
scale may lead to ambiguity (40). The scale must have suffident
range in order to encompass the spectrum of possible responses in
the study populatioa The measure must also be able to equally
detect improvement and deterioration. Each scale should consist of
five to seven categories. A number of studies have shown that
reliability falls as less categories are used, particularly with less than
five scales. An upper limit of 10 to is categories bas been suggested
to reduce confusion and complexity (1). Finally, scales should be
symmetrically designed. An asymmetric scale may bias results. For
example. the following scale used in a clinical trial (excellent, good,
no change. v.urse) provides tYIO opportunities for improvement and
only one for deterioration. This increases the likelihood of a positive
response and may introduce bias (40).
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2 S' Pretesting'
Pretesting a group of respondents similar to those alxmt to be
studied can identify potential problems or misunderstandings.
Confusing or embarrassing questions can be detected. This process
generally involves testing a random sample of a few to as many as
20 patients. Poor wording or choice of response options can lead to
incomplete use of all possible responses in a question. Qllestions can
be examined to ensure that a full range of response options are used.
Any modifications required can be retested prior to use.
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2 6- ReprodudhiUry and Responsiveness:
An instrument must be proven to be reprodudble (reliable) and
responsive to change before use in a clinical ttiaL To demonstrate
reliability or reproducibility. the questionnaire must be repeatedly
administered to a group of patients who are deemed to be stable. The
intervals and number of administrations should mirror what is
planned for the clinical trial. The minimum interval between
administration should be at least one week. The data from this srudy
will yield an estimate of the variability in stable patients and hence
an indication of the reliability of the instrument (26). Reliable
instruments will generate similar results in stable subjects on
repeated administrations of the instrument.
A second assessment is required to evaluate responsiveness. In this
instance, the questionnaire is given to patients similar to those in the
planned trial before and after utilization of an intervention known to
be efficadous. Ideally, the instrument will show not only
improvement in symptom scores, but also a suffidently large
improvement relative to the Variability shown by stable patients.
The ratio between the change seen in the second study (patients who
change with treacment) to the Variability in first srudy (stable
patients) provides an estimate of questionnaire responsiveness. The
larger the difference in instrument score in the group with real
change (the signal) the greater the responsiveness of the instrwnent.
As the difference in score in subjects who are stable (the noise)
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becomes larger, the reliability of the instrument becomes lower and
hence the instrument less responsive (26).
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27: Validity:
The easiest means of demonstrating validity is to compare to an
accepted reference measure or "gold standard." Unfortunately, a gold
standard is usually not available. [n this case, a researcher should
use construct validity. Does the instrument behave in relation to
other measures as one would expect? Construct validity involves
comparisons between measures with examination of the relationship
hypothesized to exist bet¥Jeen the measure and its constructs (26).
Since evaluative instruments measure change, the relationship of
change in the instrUment and change in other variables should be
evaluated and compared. (37). Validity of an evaluative instrument
can be demonstrated by showing that changes in the instrument
correlate with changes in other related measures in the predicted
amount and direction.
Construct validation was used to assess validity during the
development of the Inflammatory Bowel Disease Questionnaire (39).
The !BDQinduded 30 items directed at four domains: bowel
symptoms. systemic symptoms, emotional function, and social
function. The !BDQwas administered to 42 patients with !BD and
repeated one month later. In addition, the investigaton applied
patient-based global ratings of change in function, global ratings of
change by the physician and relative, a disease activity index, (41,
42) and the emotional function domain of a general quality of life
measure (43).
2S
At the time the investigation was planned, the investigators made
predictions about how the IBDQ.shouid relate to changes in the other
measures if this questionnaire 'WaS measuring quality of life. An
example of the predictions made was that the patient's global rating
of change in disease should correlate dosely (correlation coeffident >
0.5) with change in the bowel symptom dimensions of the IBDQ. Of
the 10 predictions made in this s01dy, 3 were correct. In five,
correlation 'WaS slightly lower than predicted. The authors conduded
the results provided moderate suppon for the validity of the
questionnaire.
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Chapter 3: STATISIJCAL ISSUES"
3.1' Introduction"
There are a number of statistical issues which should be addressed in
the development of a subjective instrument for use in a clinical trial.
Reliability. responsiveness, and validity need to be demonstrated and
the role of the measure as a discriminative or evaluative instrument
should be considered. If the instrument's role is to d.iscriminate
among subjects, between subject variability is important. For an
evaluative instrument where change within subjects is important,
the ability of the instrument to detect change must be quantitated.
Finally, issues germane to use of the instrument in a controlled
clinical trial such as sample size calculation will be discussed.
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3.2' Reproducibility:
Reliability, or reprodudbility is determined by the extent that a
measuring procedure yields the same results on independent
repeated. trials under the same conditions (44), Repmdudbility can
be measured by serial administration of a test to a group of subjects
believed to be stable. For parametric data produced by most quality
of life instruments, reprodudbility can be quantitated by Pearson's
correlation coeffident (r) (45). The Spearman rank correlation
coeffident provides a similar assessment with nonparametric data
(46).
Measures of internal consistency such as Cronbach's alpha (47) have
been commonly used in the literature to test the reliability of a
measure. These measures can be calculated from a single
admioistration of a questionnaire without the requirement of two or
more administrations. Sources of variance which occur from day to
day do not enter into the calculation of these measures.
Consequently, measures of internal consistency should not be used to
assess reliability of a subjective health measure (1).
Pearson's correlation coeffident can be used to quantify reliability,
howe:ver it fails to take into account Variability in results attributable
to systematic, as opposed to random, differences in test scores with
multiple applications. Such systematic changes can be produced by
learning effects, for example. Pearson's r is also restricted to the case
of two measurements per subject (36).
28
The intradass correlation coeffident (ICC) which reflects both
systematic and random differences in test scores is now generally
accepted as the preferred method of quantitating reliability (48). The
ICC can be calculated as the ratio of the variance in subject score
attributable to characteristics of the subjects to the total variance in
score (induding variance amibutable both to between subject
difference and to differences among subjects) over multiple
repetitions of the test. Therefore, rather than measuring the
correlation between two sets of scores (as with Pearson's r), the
intradass correlation coefficient tells about concordance or the extent
to which repetition of the test yields the same values under the same
conditions in the same individuals. The ICC is applicable no matter
how many measurements per subject. as long as there are at least
two (36). For these reasons, the intraclass correlation coeffident is
the recommended statistic t:o assess the reliability of an instrument.
29
3 3' Resooosiveness'
To use quality of life and symptom-based assessmeots in a clinical
aial. the researcher needs an evaluative instrument which is capable
of detecting change within subjects over time. Measuring only the
reliability of such an instrumeot is inadequate wheo assessing tbe
usefulness of an instrument for this purpose. The likelihood of
detecting clinically important treatment effects or the instrument's
responsiveness must also be assessed.
Researchers have most commonly demonstrated responsiveness by
comparing instrument scores before and after an intervention. An
improvement in score would be evidence of responsiveness. At-test
has beeo used to detect significance. Wheo trying to select tbe best
instrument among several possible choices. the instrument with the
largest paired t-statistic is judged the most responsive (13).
However, this method does not account well for variability in scores
that may occur in appareotly stable patieots (learning effects for
example).
Another method which has been used for comparing responsiveness
of competing measures is the effect size. Effect size relates changes in
mean score of the instrument (from baseline measurement to
measurements after the intervention) to the standard deviation of
baseline scores (49). The usual calculation of tbe effect size takes tbe
difference in means and divides it by the standard deviation of
baseline scores. This transforms score change into a unit of
measurement which could be compared with score changes of other
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instrUments (50). This statistic has been widely used in the sodaJ
sciences.
A variant of the effect size has been suggested by Guyatt with a
different denominator: the standard deviation of score changes
among stable subjects. Guyatt and colleagues suggest that
responsiveness is not a function of the baseline standard deviation of
scores but of the variability in score changes for stable subjects (36).
This approach acknowledges that there is some noosped.fic
Variability in scores and that to be truly responsive an instrument
must detect changes above and beyond this nonspecific degree of
change. This responsiveness index has been referred to as the Guyatt
responsiveness statistic (SO).
When stable subjects not exposed to an intervention are repeatedly
given the same questionnaire over time, there are inevitably changes
seen in question.naire scores. This can be due to a number of factors.
A learning effect with repeated administtation of a questionnaire
may improve scores. In the setting of a clinical trial, improvements
may be seen due to placebo and Hawthorne effects (51). The
Hawthorne effect is defined as the tendency for people (Q change
their behaviour because they are the target of speda1 interest and
attention in a study (52). The Guyatt statistic has the advantage of
accounting for nonspecific score changes often noted in patients who
are clinically unchanged (50).
Guyatt's variant of effect size can be calculated in the following
manner. The same numerator for effect size calculations is used. that
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is the difference in means measured before and after an
intervention. and is divided by the standard deviation of score
changes for s"'ble patients. It sbould be noted tbat this smndard
deviation is equivalent to the square root of twice the mean square
error. The data. for calculation of the numerator should be obtained
from study subjects who have demonstrated improvement from the
intervention by some external criterion. Deyo suggested patient-
clinician consensus to select the subgroup of improved patients for
estimating responsiveness or more properly effect size (50). The data
for calculating the standard deviation of score changes in stable
subjects can be obtained from the subset who did not improve with
the intervention. Alternatively, this information could be obtained
from data used to calculate reliability statistics (untreated subjects).
Determination of the responsiveness statistic allows comparison
among measures. This information also permits sample size
calculations for future clinical trials.
A potential disadvantage of effect size and the Guyan statistic as
calculated is that the score change in the numerator may actually
overestimate treattnent effects. This may arise because some change
is often noted even in stable patients. In order to adjust for this
potential overestimation, the difference in score change observed in
stable subjects should be subtracted from the numerator of either
statistic. Subtracting this value from the numerator allows calculation
of a revised. effect size and revised responsiveness index wJ:rich may
be better estimates of the true treatment effect.
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3.4: Sample Size Calrulation'
In order to determine the sample size or number of subjects needed
for future clinical trials, the t\'\O parameters used to calculate the
responsiveness index can be used. These are the m.ini.m.um clinically
important difference and the variability in stable patients or
h/(2MSE) (36). If the responsiveness of an instrument is known. one
can choose the sample size required for an experiment where change
in test score over time is the endpoint and in which pre and post
treatment scores are available.
Generally the change in score that is the minimwn clinically
important difference is not known. This difference can be estimated
by determining the change in score observed after an intervention of
known efficacy. If a poor choice is made and the treatment does not
work, responsiveness will be under estimated. There is no
standardized method of estimating this value. Surveys of subjects
particularly those who rate themselves as a "little improved" may
provide better estimates of this value. Final estimation requires
further information from future clinical trials and surveys of patient
opinion regarding what and how much are important differences in
their symptoms.
The second parameter required is the mean square error (MSE) or
variability in stable patients. As mentioned in the previous section,
the standard deviation equals the square root of twice the mean
square error. The MSE can be calculated in the following manner.
Simply squaring both sides of the equation results in the variance
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equal to twice the MSE. Dividing each side of the equation by 2 gives
the formula for MSE - 52/2 where s is the standard deviation or 52
the variance.
Knowing the resIX>nsiveness index (Guyatt statistic) allows
determination of sample sizes required for further trials using the
evaluated. instrument. If the variability in stable patients is small
relative to the subject score which constirures a clinically important
difference or treatment effect. a clinical trial could be conducted with
small numbers. Guyan bas demonstrated such calculations and
generated an illustrative table (see Table 3.1 below). The fonnulae
used for sample size calculation for independent groups and for
related groups are as follows: 2[(Za + Z/!)al"F and [(za + ZMal"F
where a is the probability of erroneously conduding the treatment is
effective, ~ is the probability of erroneously conduding the
treatment is ineffective. 6. is the minimum clinically important
difference, and a the variability in stable patients or "'(2xMSE) (36).
Note that in Table 3.1. n is increased according to che methcx1 of
Lachin when sample size is less than 30 (53). This explains the odd
numbers generated in this table.
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Table 3.1' sample Size calculations Using Guyatt's Resoonsiveness
Ind ( 005 (1 tailed). 0 1mex: assumptions: a_ -
Guyatt Sample size required Sample size required
Responsiveness for independent for related groups
Index groups
(AN2xMSE)
2 7 S
1 19 11
0.8 29 16
0.6 48 26
05 68 34
0.4 107 S4
0.2 428 214
adapted from (36).
In the above table of sample size calculations, a one-tailed alpha was
used. This assumption is reasonable in the instance where the
investigator is interested only in detecting change in one direction
such as when using a health instrument to only detect symptom
improvement after treatment. The investigator would consider
worsening of symptoms the same as no response to treatment,
Conventionally most studies are designed to detect improvement or
worsening of the outcome being measured. This calls for use of a
rwo-tailed alpha which will increase the necessary sample size.
Sample size calculations using a tM>-tailed alpha are illustrated in
Table 3.2 below. The value of n is increased according to lachin's
method as in the previous example.
3S
Table 3 2: Sample Size Calculations Using GUyatt's Responsiveness
Ind 0 OS 2 tailed) 0 0ex: (assumptions: a _ ( ·8_ .1 )
Guyaa Sample size required Sample size required
Responsiveness for independent for related groups
Index groups
(AN2xMSE)
2 8 6
1 23 13
0.8 34 18
0.6 58 31
0.5 84 42
0.4 132 66
0.2 524 262
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Chapter 4: NON-ULCER DYSPEPSIA:
4 l' IntroductiOn:
The functional bowel disorders are a group of gastrointestinal
conditions for which no structural abnormality is known to be the
cause. These are important entities because of the frequency with
which they occur in the general population. Nonulcer dyspepsia, one
of the functional bowel disorders, is defined as chronic or recurrent
(greater than three months duration) upper abdominal pain or
nausea which mayor may Dot be related to meals (54). The cause of
nonulcer dyspepsia is unknown although a variety of abnormalities
such as delayed gastric emptying, hypersensitivity to gastric
distention, and He1icobacter pylori infestation are found in variable
numbers of patients (54, 55).
The costs to the health care system related to nonulcer dyspepsia are
staggering. The point prevalence of dyspepsia (upper abdominal pain
or discomfort) has been estimated to be Z5% with an annual
inddence of Z-8% (56). Up [05% of primary care visits are for
dyspepsia of which 60% have no organic explanation. The majoIiry of
dyspeptic patients will receive a prescription. Patients with
functional dyspepsia are two to three times more likely to be off
work for health reasons (57).
Patients diagnosed with nonulcer dyspepsia have a variety of
complaints. These may indude abdominal pain, nausea, bloating,
early satiety and retching. Because of the diversity of complaints
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suffered by nonulcer dyspepsia patients, it is difficult to conceive of
one unifying hypothesis to explain this condition. In fact. nonulcer
dyspepsia may represent a number of different conditions. In an
attempt to darify and categorize nonulcer dyspepsia patients with a
view to aiding therapy, a number of subgroups have been proposed.
In 1988, an international working group proposed a dassification of
nonulcer dyspepsia subgroups based on symptoms (see Table 4.1,
appendix) (58). These criteria have been more recently reviewed and
updated (59).
Based upon this classification of nonulcer dyspepsia patients, therapy
has been directed towards the specific symptom subgroup. Patients
considered to fall in the ulcerlike subgroup have received therapy
directed to add suppression with agents such as the HZ blockers or
proton pump inhibitors. Patients suffering from motility like
symptoms have been treated with prokinetic agents such as
Cisapride or Domperidone. The available evidence suggests this is a
reasonable approach (60-65).
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4.2' Critical Appraisal of the literature:
A large number of clinical studies have been performed and
published in an attempt to determine potential treatments for
patients suffering with nonuIcer dyspepsia. To date, there is no
definitive evidence for an efficadous treannent.
A number of aitidsms of the current nonulcer dyspepsia literature
have been put forward. by Veldhuyzen van lanten et al. in a recent
systematic review (66). The following information is condensed from
Veldhuyzen van lanten's work.
Fifty-two randomized trials were identified of which 36 were
placebo-controlled trials and 16 cross-over design studies. A variety
of symptoms were measured in these trials. Forry-nine trials (94%)
measured epigastric pain, 38 (73%) trials nausea. 29 (56%) trials
heartburn. 25 (48%) trials bloating, and 28 (35%) trials belching.
Categorical scales were the most common type of outcome measure
used in 34 (65%) trials with use of symptom severity the most
widespread. Thirteen (25%) trials assessed symptom frequency and
only 5 (1096) estimated symptom duration. Four point categorical
scales were the most popular. Only 5 studies used 5 or 7 point scales.
Visual analog scales were used in 6 (12%) studies.
Patient based global assessments of overall symptom severity were
used in 19 (37%) of the identified studies. in 14 of these 19 trials,
the subjects were asked to make a global assessment of change in
symptoms after the treatment had been received, without a baseline
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assessment before the intervention. Eght trials (1596) used a
physician-based global assessment as an outcome measure.
The major flaw in this body of literature was the lack of validation of
outcome measures prior to their use in a clinical trial. Only 5 studies
used outcome measures which had been previously validated. in a
pilot study (67-71). Of these 5 trials. 4 were multiple cross-over
trials. To date, mere has only been one placebo-cootrolled, not cross-
over trial using previously validated outcome measures in nonulcer
dyspepsia (67).
Ve1dhuyzen van lanten and others have made a number of
suggestions for future research in this area. Most studies do not
dearly state whether enrolled patients were obtained from primary
or tertiary practice. The patient setting should be dearly described to
be aware of potential problems with patient selection and referral
bias. A variety of definitions of nonulcer dyspepsia have been used.
affecting reprodudbility of results. It has been suggested. by
Ve1dhuyzen van lanten that the Rome criteria for diagnosis of
functional dyspepsia be adopted (59). Additionally, these expertS
have advised that patients diagnosed with the Irritable Bowel
syndrome (IllS), as assessed by three or more of the Manning (72) or
Rome criteria for IBS (73), be excluded from future studies of
nonulcer dyspepsia..
There is consensus that a thorough workup is required. Nonulcer
dyspepsia symptoms mimic other organic conditions. The diagnosis of
NUD is ooe of exclusion. A minimum set of investigations should
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include endoscopy and basic laboratory screening. Patients must
have symptoms severe enough to seek medical attention and must
still be symptomatic at the time of enrollment.
A set of exclusion criteria bas also been recommended by
Veldhuyzen van lanten and his co-authors. These indude the
following: 1) history of, or evidence of esophagitis; 2) history of, or
presence of gastric or duodenal ulcer; 3) endoscopic evidence of
gastric erosions; 4) endoscopic duoo.enal erosions; 5) history of
previous upper GI surgery; 6) daily use of a nonsteroidal anti-
inflammatory drug (NSAID); 7) suspected or known alcoholism; and
8) presence of the irritable bowel syndrome.
Perhaps the most important recommendation is that all future tIials
should be randomized, placebo-controlled trials. The placeho
response in NUD trials varies from 13 to 73%. Cross""ver designs are
not recommended for research in functional dyspepsia. [n studies of
cross""ver design. each subject receives both treatments being
compared in the clinical trial. Cross""ver designs allow comparison of
within patient differences rather than benveen patient differences of
placebo-conrrolled trials. Consequently smaller sample sizes are
required. Cross""ver studies call for stable, usually chronic disease
during bam treatment periods and a similar baseline condition
present at the stan of each treannent period. If the patient baseline
differs markedly at the start of each treannent, it is impossible to
compare the t\\O treannents. Finally, there should be no carry over
effects after either treatment. This means that all disease
manifestations revert {Q baseline and all the effects of previous
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treatment disappear after cessation of therapy (74). Since the
variability of symptoms in NUD can be substantial and because it is
uncertain if patients will go back to baseline after a wash-Qut period
post-treatment, Veldhuyzen van lanten and co-authors have
recommended that cross"ver designs be avoided (66).
Another problem in this area of research is the tremendous variation
in the use of outcome measures, induding which symptoms are
assessed and how symptom severity is measured. This same group of
authors have recommended the use of 5 to 7 point categorical scales.
These scales are more responsive than smaller scales. There has been
no agreement how to measure symptoms, however an assessment of
severity must be done at baseline before any intervention and
symptoms must be of suffident severity to allow documentation of
any improvement. Patients with mild dyspepsia have little room to
improve even with a truly effective drug. An overall subject-based
global assessment of symptom severity should be induded rather
than using multiple symptoms to avoid potential problems with
multiple comparisons. Physician-based assessments of overall
symptom severity should not be used as the main outcome measure
because there may be substantial inter-and intra-observer variation
in physician recording of symptom severity. Physidan assessments
may be useful as secondary outcomes.
The final recommendation of this paper is that all subjective
measures used to determine outcome must be validated prior to use
in a clinical. ttial. lbis process involves the demonstration of
reliability, responsiveness, and validity of the measure (66).
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4.3: Available Outcome Measures·
The major weakness of this body of literature. as already stated. is
the almost complete lack of use of validated oureome measures. By
the very subjective nature of the functional bowel diseases.
quantification of response to therapy is extremely difficult. The main
focus of the nonulcer dyspepsia literature has been the
establishment of the diagnosis of nonulcer dyspepsia. In recent
years, investigators have taken some interest in the development
and validation of outcome measures to evaluate symptom severity
(66). To date, there are two fully published reports describing
symptom-based outcome measures (75. 76) as well as a condition-
specific measure which has not yet been fully validated (77).
Nyren et a1 developed a multidimensional symptom score for
epigastric pain labeled the OIBS (duration-intensity-behaViour scale)
(75). The DIBS scale \'VaS a seven point adjectival scale. This scale was
developed by comparing epigastric pain response to antadd therapy
for three weeks in 32 patients with functional epigastric pain. The
pain index (the procluet of pain intensity and duration) in the OIBS
was compared to a concurrently administered visual analog scale. A
high degree of concordance among the scales was demonstrated and
both were determined to be sensitive to change.
The OIBS has been used subsequently in a randomized controlled
trial of 3 weeks of treannent with Cimetidine. antadd. or placebo in
159 nonulcer dyspepsia patients. The primary outcome \VaS decrease
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of epigastric pain. No significant difference was demonstrated
between the three groups studied (67).
Nyre.n's paper has been criticized for the use of only one symptom
(epigastric pain). Patients with nonulcer dyspepsia may suffer from a
variety of other complaints such as nausea or bloating. It is not dear
if epigastric pain alone is a suffident indicator of functional
dyspepsia. However. by focusing on a single symptom, the multiple
comparisons seen in many nonulcer dyspepsia trials were avoided. It
is unreasonable to assume that the symptoms of nonulcer dyspepsia
are independent of each other. Using multiple symptoms as separate
outcomes increases the possibility of conduding active treatment is
superior to placebo simply by chance alone. This can be avoided by
correcting for multiple comparisons by using statistical corrections
such as the Booferroni or Tukey corrections (78, 79) or instead by
using a global measure of symptom severity as the primary outcome
measure (66).
Veldhuyzen van lanten published a symptom-based outcome
measure for nonulcer dyspepsia patients following the guidelines
established by Guyan (26) for the development of disease-specific
measures (76). This group looked at patients with Helicobacter pylori
-associated gastritis and nonulcer dyspepsia (Helicobaccer pylori
negative patients). The objective of this work was to select
gastrointestinal symptoms and establish that these symptoms
recorded as 5-point adjectival scales would meet criteria for use as
outcome measures in clinical trials. Symptoms 'Were selected from
the literature and a pilot group of 24 patients 'Were used to reduce
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the number of items for the questionnaire. The 8 symptoms with the
highest cumulative scores (the product of severity and frequency)
were selected for use. A second group of SS patients was studied to
test reprodudbility, responsiveness, and validity of the preferred
items. Patients with the irrttable bowel syndrome and non-steroidal
anti-inflammatory drug users were excluded, as was anyone with
abnormal endoscopy. He1icobacrer pylori status was determined.
Symptom severity was measured at study entry (Tl), at one week
before O"eannent was given (T2), and at 4 weeks after treattnent
(T3). He1icobaccer pylori positive patients received Pepto-Bismol and
Ampidllin and Helicobacter pylori negative patients received
antadds or H2 blocker therapy. Reprodudbility was tested by
comparing repeated measurements before intervention (Tl and T2).
Responsiveness or ability to detect change was assessed by
comparing scores immediately before (TZ) and after (T3) treatment.
Validity was determined by comparing scores with changes in
general health status measured by patient global assessments. The
authors conduded that scoring gastrointestinal symptoms using 5-
point adjectival scales satisfied the 3 criteria for use as outcome
measures.
This study was methodologically very sound, however it is not
without problems. Three of the 8 symptoms selected (heartburn,
sour taste, and halitosis) are symptoms of add reflux, not nonulcer
dyspepsia. At the time this study was ongoing, patients with
symptoms of add reflux and nonna! endoscopy were considered to
represent a reflux-like subgroup of nonulcer dyspepsia. Veldhuyzen
4S
van Zanten, Talley, and others have since convindngly argued against
the existence of this subgroup and have stated that patients with
heartburn as the predominant symptom should not be induded in
studies of nonulcer dyspepsia (66). Many patients with pathologic
add reflux do not have endoscopic evidence of esophagitis (54. 59). A
study has demonstrated that heartburn and add regurgitation as the
dominant symptoms are very specific (85% and 96%) for a diagnosis
of gastroesophageal reflux disease (GERD) (80). In other words, if
these symptoms are present the patient is likely to have add reflux
disease. Therefore it has been recommended to exdude patients
whose predominant symptoms are heartburn or acid regurgitation
since they have GERD, not NUD (66). Following this argument, many
of the symptoms used in Veldhuyzen van l.anten's outcome measure
should be exduded.
The most recent publication in this area is that of an ongoing
development of a condition-specific questionnaire for dyspepsia and
ulcer-related symptoms (77). Items have been selected by literature
review with analysis by content expertS and pretested with a small
patient sample. Testing was performed by mailing the new
questionnaire and a previously developed generic questionnaire (SF-
36) (81) to identified referral patients from primary care. Initial
items were rejected if too much correlation with other items was
documented. In other words, little further information would be
added with indusion of these items in the questionnaire. A
subsample received the revised second questionnaire along with the
global assessment to test reprodudbility. Validity was tested by
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comparing the new questionnaire with the concurrently
administered generic health survey. Responsiveness has not been
tested to date with further questionnaire development ongoing.
This questionnaire induded items regarding epigastric pain and
assodated features (location. severity. frequency) as well as
symptoms such as vomiting. melena. hematemesis. and weight loss.
Heartburn had been exduded. Many of these symptoms would not be
seen in nonulcer dyspepsia patients. In fact, their very presence
would be indicative of serious organic disease and consequently
exdude the diagnosis of NUn. In addition. other symptoms commonly
seen in nonulcer dyspepsia are not included, for example. many
fearures of dysmotility induding nausea and bloating. Consequently.
this questionnaire is not appropriate for use in nonulcer dyspepsia
trials.
In conclusion, no appropriate outcome measure exists for use in
clinical trials of nonulcer dyspepsia. Therefore. a new symptom-
based measure is required.
47
Chapter 5: OBlECTI'IES-
5 1: Study Objective:
The main objective of this study was to develop a symptom-based
outcome measure for future use in nonulcer dyspepsia trials. The
outcome measure was designed using the recommendations of
Veldhuyzen van Zanten and others for NUD tIiaIs. As part of this
process, this measure would have to be shown to be reproducible,
responsive, and valid.
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OJaoter 6: METHODS:
6.1' Questionnaire DeyeloPment:
The questionnaire used in this study was developed before
commencement of the study (see appendix). The principles suggested
by Guyatt...vere used to guide questionnaire development (26). The
questionnaire was intended to be short, simple, and easy to apply. It
was directed specifically at symptoms known to be associated with
nonulcer dyspepsia. The symptoms selected were abstracted from
clinical guidelines in widespread use (58) and induded abdominal
pain, nausea, retching, vomiting, bloating, and early satiety.
Using a vartalion of a previously validated method by Nyren (75),
each study participant was asked to select their most important
symptom from the list provided. Nyren used only abdominal pain as
the marker for response to therapy in nonulcer dyspepsia patients
(75). His primary outcome measure was the product of abdominal
pain intensity and duration (combined score). Since only using
abdominal pain exdudes a number of nonulcer dyspepsia patients. in
particular the subgroup with motility symptoms such as bloating,
nausea, or early satiety, the participants in this study 'Here asked to
select their most significant complaint or symptom. The selected
complaint was used as the individual's indicator of response.
For this study, the frequency and severity of the selected symptom
were recorded on S-point adjectival scales. Scores were assigned as
follows: none= 1 point, once per wee.klmild... Z points, most
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days/moderate= 3 points, daily/severe= 4 p::>ints, and more than
once each day/very severe- 5 points. Five point scales 'Were used
since this outcome measure has previously been demonstrated to be
reprodudble and responsive when measuring individual
gastrointestinaJ symptoms (76). The frequency/severity product was
calculated and recorded as a estimate of the participant's present
condition. Using the product score increased the range of possible
results from 1 to 25. Since both frequency and severity were
measured using the product, changes in either would be reflected in
the final score. This would be expected to result in increased
sensitivity to change of the patient's symptom. Perceived changes
only in severity but not frequency would be considered a change for
the patient but would not be detected by an instrument measuring
frequency only. The product of frequency and severity of the
subject-selected symptom was the primary outcome measure of this
study,
A patient-based global assessment of overall status was recorded
with each administration of the questionnaire using a 10 em. visual
analog scale. A VAS was chosen because of its simplidty. documented
comparable resp::>nsiveness to categorical scales (34), and avoidance
of potential 'halo' effect. The halo effect indicates the tendency of
questionnaire recipients to fill in the same position on a scale when
categorical scales are listed above and below each other on a page
(1).
Other measures obtained induded frequency of antadd
administration and physician assessment of subject'S symptom
so
severity. Antadd use, which was hypothesiZed to decrease if the
subject improved, was recorded each time with a S-poinc adjectival
scale (noc at all; once per week or less; most days but not every day;
once per day; and more than once each day). The physidan's
impression of the severity of the patient's complaints was recorded
with 5-point adjectival scales (none; minimal; mild; moderate; and
severe). Five point scales \'Vere chosen to correlate with the
previously mentioned symptom severity and frequency measures.
Smaller scales 1NeI'e not used to avoid potential loss of information
and sensitivity to change inherent in smaller scales.
Finally. in order to distinguish which patients bad. responded to their
therapy, symmetrical 7-point adjectival scales were used. Seven
point scales were selected because they should be more sensitive to
change than S-point scales. increased sensitivity to change was felt
to be important. In order (0 determine the responsiveness of the
instrument, patients who had changed with therapy had to be
selected from those who were unchanged. Physician-patient
consensus was required to determine the changed group of subjects.
Both the physidan and patient indicated whether the partidpant had
improved, had remained the same. or had 1NOrsened. The physician
was unaware of the patient's response at the time of assessment.
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6 2' Study Entry;
The patients in this study were referred from a general practice
setting to a tertiary care gastroenterology clinic. Those people who
complained of upper abdominal pain!discomfort for greater than six
months were approached about entering this study. A routine history
and physical examination was performed. Patients were excluded if
they had undergone prior gastric surgery, might be pregnant, or had
used proton pump inhibitors, antibiotics, PeptoBismol. or non-
steroidal anti-inflammatory drugs (NSAID) in the previous month.
Patients with symptoms of reflux disease such as heartbwu.
regurgitation. or 'N3.ter brash, or who required ongoing NSAID
therapy were also excluded. Finally, patients diagnosed with the
irritable bowel syndrome by the presence of three or more of the
Manning Criteria (see Table 6.1) were not considered appropriate for
this study. Subjects who gave informed consent were entered into
the study.
An endoscopy was performed as per standard practice to rule out
organic disease as the cause of tile patients symptoms and to confirm.
the diagnosis of nonulcer dyspepsia. The presence of abnormal
endoscopic findings excluded the subject from further study.
Once the diagnosis of nonulcer dyspepsia had been established. each
partidpant was categorized into either the ulcerlike or
dysmotilitylike subgroup based on the Rome criteria (58, 59). The
presence of three or more criteria (Table 4.1) was required.
Partidpants who had overlapping symptoms were classified in the
S2
category for which the most aiteria were present. The clinical
nonulcer dyspepsia subgroup was used to guide the choice of
intervention. Previous literature has documented the responsiveness
of the u1cerlike subgroup to H2-blockers (62-65) and the
dysmotilitylike subgroup to motility drugs (GO, 61), Members of the
ulcerlike subgroup received add suppressive therapy with HZ-
blockers or proton pump inhibitors. The actual drug selection was
left to the discretion of the investigator. The dysmotilitylike
subgroup received. a prokinetic agent. Cisapride or Domperidone. at
the choice of the investigator. Treatment was given in standard doses
for a period of one month. It should be noted that this was an open,
uncontrolled study with no attempt to assess the benefit of
treatment with one drug compared to another, The sultabillty of drug
selection for the different subgroups was not assessed nor were the
response rates of the subgroups compared.
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6.3' Questionnaire AdministratiQn:
The first administration of the questionnaire (Tl) was perfQrmed at
the initial visit. Patients were instructed on how to fill in the
questionnaire, with particular emphasis on how to record
information using adjectival scales, and on the proper method of
indicating overall status using a visual analog scale. The
questionnaire was self-administered by the study partidpant
without receiving further aid or intervention by the investigator. The
investigator also recorded their own assessment Qf the severity Qf
the subject's condition without prior knowledge of the partidpant's
responses.
Subjects were given a second copy of the same questionnaire and
asked to fill this in at home one...eek later (T2). The completed
questionnaires were mailed in self-addressed, stamped envelopes
which \Vere provided. No intervention was given in the week
between the first and second administration of the questionnaire.
The data gathered at this point from untreated, presumably stable
subjects, allowed assessment of the instrument's reliability.
At this point. the assigned therapy was begun for a one month
period. After one month, each study partidpant returned to the GI
clinic for assessment. A third copy of the questionnaire was self-
administered (T3). A subject-based global assessment was again
obtained on a visual analog scale and the subject also indicated
whether they had any response to therapy using a 7-point adjectival
scale. A physidan assessment of the severity of the patient's
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condition and of me subject's response to therapy were recorded by
the investigator, again without prior knowledge of me partidpant's
responses. The data obtained at this point permitted determination
of the instrument's responsiveness to change in subjects who may
have responded to treatmenL (see appendix, third section).
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6.4' Questionnaire CorreIations:
To evaluate the validity of the new measure, guidelines for strength
of correlation were modeled upon validation studies of 2 other health
measures. In the validation of the Inflammatory Bowel Disease
Qjlestionoaire (IBDQ) (39), items were considered to be dosely
related when correIation > 0.5. For example, the authors of this
instrument feit that the patient global rating of change in disease
activity ""u1d be doseiy reiated to the change in bowel symptoms
dimension of the ffiDQ. Measures were considered moderately
related when correlation> 0.4. In this instance the authors predicted
that the relative's global rating of disease activity would relate
moderately well to change in the bowel symptom dimension. Some
relationship was considered. if correlation> 0.3.
The Asthma QJJality of Ufe Qjlestionnaire was a similar instrument
deveioped for use in patients with asthma (82). In this srudy. the
authors used the following indices to determine strength of
reiationship: strongly correiated, r > 0.5; moderateiy correiated, r-
0.35 to 0.5; and poorly correiated, r - .20 to .35.
[n the present study, a variety of constrUcts were predicted. to be
related to the new measure. Based upon information from the two
previously mentioned validity trials, it was expected that patient
global assessment should be doseiy reiated to the frequency-
severity product of the subject-seiected symptom. Physician global
assessment should show moderate relationship with the frequency-
severity product. There was no previous data for comparison
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regarding the correlation of antactd use with response to treannent
in nonulcer dyspepsia patients, however it \'VaS felt that there should
be some relationship. Antacid use should decline in subjects who
have responded to the treatment received..
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65: Statistical Analysis:
Results were analyzed using a variety of statistical methods. Ordinal
data generated by categorical scales were analyzed using
nonparametric methods sucb as Spearman Rank CorreIation (46). p-
values less than 0.05 were considered to be statistically significanL
The Intraclass Correlation Coeffident was also calculated to assess
the instrument's reliability. Effect size and the Guyatt Responsiveness
statistic were calculated to assess the instrument's responsiveness
(SO). See appendix for details of the methods of calculation of these
statistics. Statistical calculations were performed using Statview v.4.5
for the Macintosh (83) on a Power Macintosh 6100 computer.
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Chapter 7: RESULTS:
7.1: Characteristics of Study Participants:
Fifty-five people were approached for this study between OCtober
1994 and November 1996. Two people refused to partidpate when
asked to enter the study. Another 9 who had given consent were
exduded after endoscopy because of abnormal endoscopic findings
(4 with duodenal ulcers. 2 with esophagitis. 1 with erosive gastritis,
and 2 with erosive duodenitis). Forty-four partidpants were enrolled
in this study and all 44 completed the first questionnaire. Thirty-
eigbt (86%) completed the second questionnaire T2 and 3S (80%)
completed the third and final questionnaire T3. Eghteen of 21 in the
ulcerlike group (86%) and 17 of 23 (74%) of the dysmotilitylike
group completed the study. Characteristics of the study partidpants
are listed in Table 3 below. The participants in the twO subgroups
were similiar with the exception of smoking which was more
prevalent in the dysmotilitylike group.
S9
Table 7 1· Patient characteristics·..
Attribute Incerlike
Dysmotilit)
Total p-value
-like
subgroup su!>2roup
Number of 21 23 44 ns
oartidoants
MeanA2e 35.5 40.5 44 ns
Female 14 17 31 os
Gender
Smoker 1 7 8 .048
Alcohol
3 4 7User ns
Other 7 5 12 ns
Medications
Caffeine 16 20 36 ns
User
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7 2' Reproducibility Statistics'
To determine reproducibility, assessment of stable patients on at
least tv-o separate occasions \oVaS required. TI and T2 assessments
were performed one week apan in patients who had received no
intervention and thus should have been stable clinically. The
frequency-severtty products obtained with the first (Tl) and second
(T2) administrations of the questionnaires are recorded in Table Al
(see appendix). The range of possible scores for Frequency and
Severity ratings are 1 to S. The frequency-severity product scores
ranged from 1 to 2S. A comparison of the scores obtained at Tl and
T2 was performed using Spearman Rank CorrelatiOD- The rho values
are listed below in Table 7.2.
Table 7.2: Comparison of symptom scores obtained 1 week apan
before thera )v received.
Category Tlmean T2 mean Spearman p-value
score score coeffident
(9S96CD
Main 3.6 3.8 .73 <.0001
Symptom (.62•.84)
Freouencv
Main 3.7 3.5 .86 <.0001
Symptom (.78, .94)
Severttv
Frequency/ 13.5 13.4 .85 <.0001
Severtty (.76, .94)
Product
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Because of the concern that the Spearman coeffident concentrates on
between subject variability rather than measuring within subject
variation the Intradass Correlation Coeffident 'naS also calculated
(SO). See appendix for detailed description of calculation of this
statistic. The calculated ICC's for symptom scores are listed in Table
7.3 below.
T.hl.73: orr.' orinn CnPffirip t,IIC'"
Symptom Standard Standard Standard lntraclass
category Deviation of Deviation of Deviation of Correlation
Tl (A) T2 (B) Tl-n (C) Coeffident
{9S9l>CD
Frequency LIS 1.00 0.79 0.73
(.62..84)
Severity 0.87 0.76 0.44 0.84
(.75•.93)
Product 5.90 5.23 3.29 0.83
(.74, .92)
62
7 3: Responsiveness Statistics'
As mentioned earlier, a variety of statistical methods have been used
to determine the responsiveness or ability of an instrument to detect
change. These methods indude t-tests to compare sample means.
indicators of effect size, and the responsiveness index, a modified
effect size statistic proposed by Guyatt. T-tests were not used in this
study since there was no other subjective outcome measure available
for comparison.
In order CO be able to assess the responsiveness of an instr'UID.ent,
evaluation needs to be performed on patients who have improved
upon receiving an intervention of known efficacy. The data used in
the following analyses was obtained from partidpants who were
considered to have responded to the therapy they had received. The
27 partidpants who had improved as indicated by both patient and
physidan global assessments were selected. Fourteen of 18 (78%) of
the ulcerlike subgroup vvere judged to have improved with
treaanent as did 13 of the 17 (76%) in the dysmotilityJike subgroup.
Of the eight subjects judged not to have improved, only one indicated
improvement by patient assessment but not physictan assessment.
The remaining seven were unchanged by both assessments. The
resulting data (see Table A 2, appendix) was analyzed to determine
the effect size and Guyatt responsiveness statistic which are listed in
Table 7.4 below. It should be noted that three subjects #9,#22, and
#29 did not complete the mail-in questionnaire (n) but did
complete £he final questionnaire (T3) after receiving treaonent.
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Consequently these subjects were not used in the calculation of
reliability (Table AI) but were used to calculate instrument
responsiveness (Table All.
Table 7.4: Resooosiveness Statistics.
Variable Effect Size Guvatt Statistic
Freouencv 1.5 1.2
Severit\l 1.4 1.1
Product 13 2.1
Revised Product 1.2 2.1
From the data one can see that each variable assessed was quite
responsive to change. The frequency-severity product seemed to be
the most sensitive to change. more than either symptom frequency
or severity.
As previously mentioned., the effect size and the Guyan statistic as
calculated may actually overestimate treaonent effects. To adjust for
this the difference in score change observed in stable subjects was
subtracted from the numerator of each statistic. The score change in
stable patients in this study (before the intervention was received)
was calculated to be 0.1 (see Table AI, appendix). Subtracting tbis
value from the numerator allowed computation of a revised effect
size of 1.2 and a revised responsiveness index of 2.1 (see Table 7.4
above).
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7.4: Validity:
In order to validate a new symptom-based outcome measure, the
newly developed instrument needs to be assessed. preferably by
airman validity. Criterion validity involves comparison of the new
measure against a reference measure that evaluates the same or
similar features (28), This might, for example, consist of comparing
the new instrument to a generic measure. There was no accepted
generic measure of this type in nonulcer dyspepsia available for
comparison. COmparison ro other dis~spedficinstruments and
symptom-based outcome measures was not performed because of
the limitations of the existing instruments as previously discussed.
These limitations induded exclusion of certain oonulcer dyspepsia
symptoms and inappropriate inclusion of gastroesophageal reflux
disease patients.
Since demonstration of criterion validity was not an option, construct
validation'A'aS used. Construct validation involves comparison of
changes in the new inscrument with changes in other measures
induding subjective assessments by a physidan. relative. or the
patient. If the measure is valid, improvements in the subject'S status
as indicated by the frequency-severity product should correlate with
improvements as indicated by the constructs. To demonstrate
construct validation of this instrument, the subject-selected symptom
was compared with patient global assessment, physician global
assessment, and assessment of the subject's antacid use.
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The difference in pre- and post-treatment patient global assessments
ranked by visual analog scale was assessed and compared with
change in instrument scores of the frequency-severity producL The
correlation coefficient r- .596 (p- .00(5) indicated that patient global
assessment by visual analog scale and the frequency-severity
product were dosely related.
The second construct assessed. was a patient assessment of change in
status after treatment recorded on a 7-point adjectival scale. It
should be noted that higher frequency-severity product score
differences indicated. improvement whereas lower scores on the
adjectival scales indicated. improvement. The Spearman rank
correlation with change in instrument scores pre- and post-
treatment was f= -.584 (p- .0007). The negative correlation
coeffident in this instance indicates that high values of one variable
tested (product differences) correlated with low values of the other
variable (adjectival scale) (84). The assignment of values to the
adjectival scales could be arbitrarily changed to give a positive but
equivalent correlation coefficient. In this case, high product values
\'\'QuId correlate with high values on the adjectival scale. The f value
obtained by this comparison indicated. the frequency-severity
product and patient assessment of response to therapy by adjectival
scale were closely related.
The third construct used for comparison was a physician global
assessment of the subject's status. The physician assessment was
compared to the change in insttument scores before and after
treatment. The correlation coefficient r~ -.437 (p- .(088) indicated
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some correlation between the instrUment and physician assessment
of patient status. In this instance, high instrument scores (proouct
differences) correlated with low physician assessment scores.
The next construct assessed was a physidan assessment of change in
status after treatment, recorded on a 7-point adjectival scale. Some
correlation with the difference in frequency-severity product was
detected with r- -.329 (p- .055).
The final construct utilized VJaS the amount of antadd consumed
before and after the intervention. Analysis was performed only on
the subjects who used antactds during the study time period The
correlation coeffictent obtained by comparing change in antadd use
with change in instrument scores r- -.143 (p:- .327). This result
indicated that there was no correlation of instrument scores with
changes in antacid use in the subjects using antadds.
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Chapter 8' DISCUSSION'
8.1: Introduction"
The purpose of this study was to develop and test a new symptom-
based outcome measure for future use in therapeutic trials of
nonulcer dyspepsia patients. In order to the confirm the adequacy of
this measure, reprodudbility, reliability, and validity of tbe
instrument had to be evaluated. A new subjective outcome measure
was tbought necessary because of tbe overall lack of validated
subjective ou[Come measures in the nonulcer dyspepsia literature
and the limitations of the pre-exi.sting measures such as inclusion of
subjects with gastroesophageal reflux and other conditions
incompatible witb a diagnosis of NUD.
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8.2: Questionnaire Design and Administration:
This questionnaire was designed following published guidelines for
develQping symptQm-based QutCQme measures in nonulcer
dyspepsia. SymptQm severity and frequency were measured by S-
point scales which have been previQusly shQ\W. tQ be a valid method
of measuring gastrQintestinal symptQms. The physidan assessment Qf
subject status and antacid use were measured with S-point scales.
Response to therapy as indicated by subject and physician were
recQrded Qn 7-point scales. The ratiQnale fQr this design has been
described. These items CQuld have been designed as 7-point scales.
This alteratiQn might have imprQved cQrrelatiQn particularly Qf the
physician assessment, althQugh the moderate correlation noted. in
this study (r~ -.437) was in keeping with physician-based
assessments in Qther published. studies. Any changes to the design Qf
the questiQnnaire 1AOuld require repeat testing in a pilQt study priQr
to use in a clinical tIial.
A visual analog scale VY'aS used to measure patient glQbal assessment.
Although a different instrument was used, the end result was similar
tQ those obtained 'Nith categQrical scales. The correlatiQn Qf the VAS
with the frequency-severity product (r= .596) and the cQrrelatiQn Qf
response to treannent measured with a 7-point scale tQ the product
(r=. -S84) were almQst identical.
The questiQnnaire was administered at entry (TI), one week later
befQre any treannent had been received (T2), and again after
treatment for one month (T3). The reasons for the timing Qf
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questionnaire administration have been described. above. Subjects
'Nere allowed to perform T2 administration at home without coming
in to the GI clinic. The study was purposely planned in this fashion to
reduce the number of clinic visits. Many of the potential participants
came from long distances. Redudng travel time ¥JaS felt necessary CO
aid recruinnent of subjects into the study.
Administration of the questionnaire at home could potentially lead to
problems. For example. there was no way for the investigators to
actually determine when the questionnaire was filled out. secondly,
the investigators could not definitively state that treatment had not
been started before the second questionnaire INaS completed. In an
anempt to avoid these problems, subjects ......ere given an assigned
date to complete the questionnaire and prescriptions for study drugs
were pr~ted to start at the correct time. Data analysis suggests
that significant effects did not arise from this design. The difference
in the means of frequency-product scores at Tl (T1 mean score
minus T3 mean score = 7.1) and T2 (T2 mean score minus T3 mean
score .. 7.3) were almost identicaL
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83: The Outcome Measure·
An adaptation of the previously validated technique by Nyren in
nonulcer dyspepsia patients was used in this study. In this case, the
main outcome measure was the frequency-severity product of the
subject-selected symptom.. The reasons for selection of this measure
have been outlined.
One potential cri.tidsm of this measure is the use of S-point scales for
measuring symptoms. seven point scales would presumably be more
resIX>nsive to change, however this did not appear to be a problem
since this instrument is quite responsive in its present format (see
below). The use of the subject's most significant symptom poses
another potential problem for this measure if subjects were to
change the selected symptom pan way through the assessment
period. 1bis did not occur during this study, as no subject changed
their selected symptom at T2 compared to Tl. This potential concern
could be avoided in future by redesigning the questionnaire so that
the frequency-severity product of all symptoms were measured. This
would increase the complexity of the questionnaire and raise the
issue of multiple statistical tests. The study partidpants were not
asked to select their most important symptom at T3 since this might
well have changed with treatment. In addition, to adequately assess
responsiveness, the measured symptoms cannot be so mild that
response to treatment cannot be measured. Using the subject's most
significant symptom avoids this potential pitfall.
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8.4: The Study Population:
Forty-four subjects diagnosed with nonulcer dyspepsia who met the
indusion criteria were enrolled in this study. Thirty-five (80%)
completed the study as per the planned protocol. Follow-up of
subjects who failed to complete the questionnaire was attempted. by
phone or mail. Dropouts were equal among the two clinical
subgroups, suggesting that the reasons for leaving the study were
not due to adverse events of one drug class or failure of Doe specific
treacment (Le. the prokinetics did not ""rk in the dysmotilitylike
subjects).
After diagnosis and enrollment each subject was classified. into a
clinical subgroup based upon predetermined aiteria (see appendix,
Table 4.1). Fifteen of the 44 partidpants bad lor 2 symptoms
compatible with the other subgroup into which they were not
dassified. Patients with overlapping symptoms were still placed into
the appropriate clinical subgroup. Since the intent was to mimic
routine clinical practice where NUD patients are treated with add
suppressive or prokinetic agents based upon the predominant
symptom pattern, no subject was excluded. None of the 15
partidpanrs with overlapping symptoms had three or more
symptoms from the other subgroup requiring categorization into
both subgroups.
The characteristics of the study subjects are listed in Table 7.1. The
subjects in each subgroup 'tYeI"e similar except that the prevalence of
smokers was higher in the dysmotilitylike subgroup. The reason for
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this difference was not obvious but may be due to the small number
of smokers in this study. One must also be cautious in interpretation
of p-values since multiple comparisons increase the possibility of
finding a statistically significant difference in one of the comparisons
simply by chance alone. Correcting for multiple comparisons using
Bonferroni's theorem (p-value for each comparison should be
multiplied by the total number of comparisons) would result in a
lower significant p-value (84), thus suggesting the observed
difference of smokers between the subgroups is not statistically
significant. A relationship between smoking and nonulcer dyspepsia
bas not been reported previously. In fact, two recent publications
suggested that there was no association between smoking and
sped.fic symptoms or subgroups of nonulcer dyspepsia (85,86).
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8.5' Instrument Reliability·
Reliability of the instrument was assessed by comparing symptom
frequency, severity, and product scores by Spearman rank
correlation. Correlation coeffidents greater than 0.7 were generated
(Table 7.2). The correlation coeffident obtained using the
frequency/severity product was 0.85. In other ¥/Ords, in stable or
untreated nonulcer dyspepsia patients, similar symptom scores were
obtained on repeated measurements one week apart. The product of
sympmm severity and frequency seemed to be a more reliable
outcome measure than symptom frequency but equivelent to
symptom severity.
As recommended. the lnttaclass Correlation Coeffident was
calculated to assess reliability. Calculating the ICes confirmed the
reliability of this instrument (see Table 7.3). Strong correlation (lCC>
0.7) was demonstrated. As noted with the Spearman rank correlation
coefficient, the frequency/severity product was a more reliable
means of assessing the participant's outcome than frequency and
equivalent to severity. The ICC of the frequency/severity product
was 0.83, equivalent to the Spearman correlation coeffident
obtained.
The ICC relates berween-subject variance to the total variance. ICC
values range from 0 to 1. When ICC values approach 0, systematic or
random differences between the baseline and follow-up scores are
present. The ICC approacbes 1 when the Variability between subjects
increases. If the ICC is bigh, as was seen with this instrument (0.81),
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lhen nO[ much of the variability is due to variability in measurement
on different occasions. III other words. reprodudbility is high (SO).
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8 6' Instrument Responsiveness:
The effect size was used. to assess the responsiveness of the
instrument. The effect size relates changes in mean score [0 the
standard deviation of the baseline scores. Partidpants who improved
(see Table Al, appendix) as indicated by an external criterion
(physician-patient consensus) were used [0 determine the effect size.
The results obtained (see appendix for method of calculation)
disclosed an effect size of the frequency-severity proouct equal to
1.3.
The effect size transfonns the score change into a unit of
measurement. IT other measures become available in future, or if
this measure underwent further mcx1ification, the effect sizes of the
new measures \YOuld allow direct comparison among measures to
determine the most responsive instrument (SO). The instrument with
the largest effect size \"K)uld be deemed the most responsive.
The responsiveness index calculated for the frequency/severity
product was 2.1. This was greater than the values calculated. for
frequency or severity alone (table 7.4), suggesting the product was
the more responsive measure. The responsiveness index of 2.1
indicated that variability in stable patients was quite small in
relation to the change in subject score. This value suggested that the
measure tested in this study (frequency/severity product of the
subject-selected main symptom) was highly responsive to change in
nonulcer dyspepsia patients.
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The difference in test scores obtained before and after the
therapeutic intervention \'V3.S actually the treatment effect of the
subjects in this study. To reliably estimate sample size requirements
for furure trials with the instrUment in question, the minimally
important clinical difference is required. This difference is said to be
the minimum change at which the patient group in question would
feel any benefit from the therapy they had received. This value is
actually not known for the patients reported in this study or for
nonulcer dyspepsia patients in generaL The minimally important
clinical difference is certainly less than the estimated treattnent
effect of this study. In an attempt to better estimate the m.inimally
important clinical difference, the product change was detennined in
the nine subjects who rated themselves "a little better" (see Table
A3, appendix). The difference in mean scores in this small subset of
subjects was 2.7 compared to the overall study score difference of
7.3. The responsiveness index in this instance equaled 0.77.
Using the responsiveness index of this instrument 2.1, sample size
calculations previously done by Guyatt (see. table 3.1) suggest that
very small samples of 5 to 10 patients per group would be required
in furure trials. If the responsiveness index of 0.77 generated from
the subjects who changed a little is a truer estimate. the required
sample sizes \'\Quid be still be in the range of 30 to 40 subjects in
each arm of the study. From this, one can conclude that the
instrument used in this study was responsive to change in NUD
subjects and that this instrUment \oVOuld be a reasonable outcome
measure for a randomized clinical trial.
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87' [nstrument Validity:
Upon demonstration of the reliability and responsiveness of
symptom-based outcome measure, the validity of the instrument
should be confirmed. The use of criterion validity was not an option
in nonulcer dyspepsia patients. Other types of validity had to be used
to assess the validity of the instrument in this study.
Face validity was apparent. This instrument was simple and easy to
use. The instrument only required a few minutes of the subject's
time. No problems in filling out the questionnaire were reponed to
the investigators by study partidpants.
Content validity, or the extent to which the domain of interest is
sampled by the instrument, was apparent. The appropriate subjects
were entered into the study by strict adherence to recommended
definitions of NUn, exclusion of organic disease in all potential
subjects by endoscopy. and usage of all recommended exdusion
criteria for NUn ttials induding non enrollment of IBS and GERD
patients. Furthermore, the subject was permitted to select their most
important symptom, without influence from the investigator.
Although the symptom was selected from a list of typical nonulcer
dyspepsia symptoms, the panidpant was not restricted to this list.
Construct validity was used to validate the instrument in this study.
Subject-based global assessments and assessments of improvement
after therapy demonstrated good correlation with the frequency-
severtty product (Ir1- .596 and .584). It should be noted that the
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results were similiar regardless of the type of measurement
used(visual analog scale versus adjectival scale). These correlations
were similar to patient-based assessments noted in the previously
meotioned validation studies (39. 82).
Physician-based assessments induding global assessments and
assessment of improvement after therapy showed less correlation to
the instrument. This was also in keeping with the experience in the
previous validation studies. The physidan global assessment was
moderately correlated with the insrrumeot (Irt-.437). Only some
correlation was noted ben.veen the instrument and the physician
assessmeot of change after rrearmeot (1rt~.329).
The final construct assessed was change in antacid use by the
partidpant. Comparing antadd use before and after the intervention
with change in the frequency/severity product revealed little or no
correlation (1rI- .143). The lack of correlation with change in anradd
use was probably explained by a relative ineffectiveness of antadds
for this condition. Antacid use by the nonulcer dyspepsia patients in
this study was noted to be rare or occasional throughout the study.
Only eighteen (S 1%) of the partidpants ingested anradds at all
during the srudy period with most of those using anradds less than
once per week. There were no obvious trends of antacid use based on
clinical subtype with eight ulcerlike and teo dysmotilirylike subjects
consuming antadds during the study. Finally, measuring antacid use
may simply be a poor construct for comparison for other reasons that
are not dear.
79
In swnmary. this questionnaire appears to be a valid measure of the
response of nonulcer dyspepsia subjects to therapy. Further study
with this measure will be required to better assess its crue validity.
Use of the instrument in randomized clinical trials and use in
different patient groups should confirm the validity of this
instrument.
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Chapter 9' eDNa IJSlON'
9 1· Conclusion:
This study documented the development of a new- symptom-based
outcome which can be used for future trials of patients with nonulcer
dyspepsia. Using techniques described by Guyatt, Deyo and others
this outcome measure met the criteria for assessment of a new
measure. In other \"lOrds. this instrument which used a patient-
selected symptom outcome was demonstrated to be reliable in stable
patients. responsive to change in patients responding to therapy. and
valid, fulfilling the required criteria for further use in clinical studies.
This instrument is suitable for application as a subjective symptom-
based. outcome measure in future therapeutic oials of nonulcer
dyspepsia.
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Al Statistical Formulae'
calculatiQn Qf the Intrac!ass CorrelatiQn Coefficjent: (SO)
1) Calculate me standard deviation for Tl, T2, and their differences
and label each subsequently as A. B. and C. Let D- the average
difference.
2) CQmpute the TQtal Sum QfSquares (S) fQr the ANOYA rable.
S-(n-I)(A2+B2) + nD2/2 where n- tQtal number Qf samples
3) The "occasiQn" sum Qf squares - nD2/2
4) The residual sum Qfsquares - (C2/2)(n-l)
5) The "person" sumQf squares - (A2 + B2 - C212)(n-l)
The values calculated above reproduce an ANOVA table.
ICC ~
where
MSP-MSE
MSP + MSE(k-l) + 2(MSO-MSE)/n
MSP- Mean Square Person
MSO- Mean Square OCcasiQn
MSE- Mean Square Error (Residual)
A simpler calculatiQn fQr ICC ""u1d be
90
ifTl and T2 were equal. then A=B. and C~o-o.The value of r - 1.
91
CalQ1lation of Effect Size: (50)
Effect Size - (U-Y)/E
where U = mean of group pre-treatment
v = mean of group post-treatment
E = standard deviation of group pre-creatment
C3J.cu1ation of Guyatt Responsiveness Statistic: (50)
Guyatt Statistic - (U-Y)/C
where U = mean of group pre-treatment
v = mean of group post-treatment
C =V2xMSE
MSE is calculated by determining the Sum of Squares (residual) and
dividing by n-1 degrees of freedom.
SS (res) - (CZ/2){n-1)
where C = standard deviation of the differences between stable
individual pre- and post-treatment.
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caJ.cuIation of sample size based on the Guvatt ScatistiC'J36l
1) for independent groups
2[(Za + ZjlJo/6J2
2) for related groups
where a is the probability of Type 1 error (false positive rate) and J!
is the probability of Type 2 error (false negative rate or power) and
a the square root of the error variance vz. x MSE.
(see above for calculation of MSE.)
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Table 4.1: Nonulcer Dvsoeosia Sut orouos:
Dysmotility-like upper abdominal palo assoc. with
bloating
nausea
retching
early satiety
tncer-like upper abdominal pain whicb is
localized to epigastrium
often worse before eating
relieved by eating or antacids
awakens from sleeo
94
T:lInle h.I: M:lInnlna Criro:-n:ll frlr rne Diaanrlcic rlf IBS.
Dain decreased with defecation
looser stools with onset of Dain
more freQuent stools with onset of pain
visible abdominal distension
sense of incomolete evacuation
oassasre of mucus oer rectum
9S
Table A 1: Stable Sub"eels before Treatment:
Sub-ect Number Baseline PT Followu PZ Difference Pl-P
1 20 20 0
2 12 9 3
3 9 12
- 3
4 9 6 3
5 15 15 0
6 16 16 0
8 15 I 15 0
10 8 9 -1
11 16 12 4
12 9 9 0
13 25 25 0
14 20 12 I 8
15 12 9 3
16 15 , 16 -I
17 9 9 0
18 I 6 I 9 - 3
19 15 15 0
20 20 20 I 0
21 I 20 12 8
23 10 10 0
24 6 6 0
26 25 20 5
27 20 16 4
28 I 6 9 - 3
30 15 15 I 0
31 9 I 12
- 3
32 12 i 12 0
33 25 25 0
34 15 12 3
35 6 I 9 - 3
37 15 , 25 -10
38 9 9 0
39 6 10 -4
40 20 20 I 0
41 12 12 0
42 6 9
- 3
43 20 20 0
44 , 6 9 - 3
Mean 13.5 13.4 Y 0.1 D
Standard Deviation 5.9 A 5.2 8 3.3 C
Variance I 34.8 27.4 I 10.9
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Table AZ: 1m oved Sub-ects at Foil After Treatment :
Sub"ect Number Baseline P1 Follow P3 Difference P1-P3
1 20 I 19
3 9 4 5
5 15 6 9
6 I 16 6 10
9 6 ! 1 I 5
10 8 4 4
12 ! 9 1 8
13 25 20 5
14 20 4 16
17 9 9 0
19 15 1 14
20 r 20 4 16
22 9 r 9 0
24 6 1 5
28 6 6 0
29 9 6 3
30 15 , 15 0
32 12 6 6
33 , 25 1 24
34 ! 15 9 i 6
38 I 9 4 5
39 ! 6 1 5
40 20 15 5
41 12 i 4 8
42 ! 6 6 I 0
43 I 20 I 6 14
44 6 6 0
Mean I 12.9 U 5.8 IVl 7.1 W
Standard Deviation! 5.8 E 4.7 6.4 G
Variance ! 33.7 , 22.4 ! 40.6
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Table A3: 'ects Who I ed A l..itde:
~ect~ Baseline Pl QneWeekP2. FoilowuD -PJ Difference Pl-P3
13 25 25 20 5
17 9 9 9 0
23 10 10 I 10 0
24 , 6 6 1 I 5
28 I 6 9 I 6 0
29 9 I 9 ; 6 i 3
30 15 15 I 15 : 0
34 I 15 ! 12 9 I 6
40 20 , 20 , 15 5
Mean 12,8 12.8 I 10.1 : 2.7
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Cl Questionnaires;
OUESTIONNAiRE #1:
1) Have you been bothered on a regular basis by any of the following
complaints? (Answer yes oc no)
-abdominal pain
-nausea
-vomiting oc retching
-upper abdominal bloating
-stomach fills up quickly when you eat
-other
2) Which one of these problems homers you the most?
3) In the past three months, how often have you had this problem?
(Cirde the best answer)
1) not at all.
2) once per week or less.
3) most days but not everyday.
4) once per day.
S) more than once each day
99
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4) [n the past three months, how severe has this problem been?
(Cirde the best answer)
1) Nopmblem
2) Mild Ptoblem can be ignored when you do not think
about it.
3) Moderate problem cannot be ignored but does not
influence daily activities.
4) Severe problem
5) Very severe
influences your concentration on daily
activities.
markedly influences your daily
activities and/or requires rest.
5) How often have you used antactds in the past week?
(Cirde the best answer)
1) nor at all.
2) once per 'Nee.k or less.
3) most days but not everyday.
4) once per day.
5) more l:han once each day
Patient Global Assessment:
Over the past week. how would you rate your stomach problem on
the follo\Ving scale?
(best it could be)
100
(..orst it could be)
Page 3
Physician Global Assessment:
Rate the severity of the patient's symptoms (as you perceive).
none minimal mild
101
moderate severe
QUESTIONNAIRE #2:
1) Have you been bothered on a regular basis by any of the following
complaints? (Answer yes or no)
-abdominal pain
-nausea
-vomiting or retching
-upper abdominal bloating
-stomach fills up quickly when you eat
-other
2) Which one of these problems bothers you the most?
3) In the past three months, how often have you had this problem?
(Cirde the best answer)
1) not at all.
2) once per 'week or less.
3) most days but not everyday.
4) once per day.
5) more than once eacb day
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4) In the past three months, how severe bas this problem been?
(Cirde the best answer)
1) No problem
2) Mild Problem can be ignored when you do not think
about it.
3) Moderate problem cannot be ignored but does not
influence daily activities.
4) severe problem
5) Very severe
influences your concentration on daily
activities.
markedly influences your daily
activities and/or requires rest.
5) How often have you used ancactds in the past~?
(Cirde the best answer)
1) not at all.
2) once per week or less.
3) most days but not everyday.
4) once per day.
S) more than once each day
Patient Global Assessment
Over the past week. how ¥/Quid you rate your stomach problem on
the following scale?
(best it could be)
103
(worst it could be)
QUEiT!QNNAIRE #3·
1) Since you 'NeI'e last seen. how often have you had your problem?
(Cirde the best answer)
1) not at ail
2) once per week or less.
3) most days but not everyday.
4) once per day.
S) more than once each day
2) Since you were last seen. how severe has this problem been?
(Cirde the best answer)
1) No problem
2) Mild Problem can be ignored when you do not think
about it.
3) Moderate problem cannot be ignored but does not
influence daily activities.
4) Severe problem
5) Very severe
influences your concentration on daily
activities.
markedly influences your daily
activities and/or requires rest.
3) How often have you used anmdds in the past week?
(Cirde the best answer)
1) not at all.
2) once per week or less.
3) most days but not everyday.
4) once per day.
S) more than once each day
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Patient Global Assessment:
Over the past week. how would you rate your stomach problem on
the following scale?
(best it could be) (""rst it could be)
4) Since you -were last seen at the GI Unit one month ago, has there
been any change in your stomach problem?
(Circle the best aoswer)
1) a great deal better.
2) moderately better.
3) a little better.
4) no change.
S) a little ""rse.
6) moderately ""rse.
7) a great deal ""rse.
lOS
Page 3
PhYSician Global Assessment:
Rate the severity of the patient's symptoms (as you perceive).
none minimal mild moderate severe
Has there been any change in the patients stomach complaint?
(Circle the best answer)
1) a great deal better.
2) moderately better.
3) a little better.
4) no change.
S) a little worse.
6) moderately WOtse.
7) a great deal \VOrse.
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Pl Nonulcer DYspepsia Patient Subgroup Classification
fuclusion Criteria;
A) UlcerUke subgroup:
Dyspepsia (recurrent upper abdomiDal pain> 3 montbs)
and 3 or more of the following:
yes no
painldiscomfoIt ac meal or when hungry
night pain (waking from sleep)
pain decreased with antadd
periodic pain/discomfort
well-localized pain/discomfort
B) Dysmotiliey subgroup:
Dyspepsia (recurrent upper abdomiDal pain> 3 montbs)
and 3 or more of the following:
yes no
nausea at least once a month
retching/vomiting at least once a month
upper abdomiDal bloating
abdomiDal pain worse witb food/milk
early satiety
pain worse!discomfon worse after meals
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Exclusion Criteria;
• Documented organic disease at endoscopy.
• Prior gasttic surgery.
• Pregnancy.
• Use in the past one month of
Omeprazole
antibiotics
Pepto-Bismol
• Continuing use of NSAID.
• IRS patients (3 or more of the Manning criteria)
pain decreased with defecation
looser stools with onset of pain.
more frequent stcx>!s with onset of pain.
visible abdominal distension.
sense of incomplete evacuation.
passage of mucus per rectum.
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EJ Para Sheets:
PATIENf DEMOGRAPHICS
Name:
Age:
Sex:
MCPII:
Home Address:
Phone It:
Medications:
Smoker.
Alcohol consumption.:
caffeine consumption:
Concurrent medical problems:
Amount smoked:
Date seen:
Questionnaire # 2 to be filled out and returned on;
Follow-up visit on:
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Fl Computer SQfuvare used:
Abascus Concepts Statview v.4.5 for the Macintosh
Claris Filemaker Pro v.3.0 for the Macintosh
Microsoft Excel vA.O for Apple Macintosh
Microsoft Word v.5.1 for the Macintosh
Niles and Assoc. EndNote Plus for the Macintosh
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NAME
BIRTIIDATE
PlACE OF BIRTH
CITIZENSHIP
HOME ADDRESS
HOME TElEPHONE
BUSINESS ADDRESS
BUSINESS TELEPHONE
BUSINESS FAX
lANGUAGE
MARITAL STATUS
~ Garth MacIntosh
Sept. I, 1958
Montreal, Ql1ebec
Canadian
18 Larch Place
5t. John's, NF.
AlB IRS
(709) 726-4389
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